Aprio Wealth Management LLC Buys 10,695 Shares of Bristol Myers Squibb Company $BMY

Aprio Wealth Management LLC increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 15.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,607 shares of the biopharmaceutical company’s stock after acquiring an additional 10,695 shares during the period. Aprio Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $4,967,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Davis Asset Management L.P. purchased a new stake in Bristol Myers Squibb during the second quarter worth approximately $27,000. Addison Advisors LLC purchased a new position in Bristol Myers Squibb in the second quarter valued at approximately $32,000. Groupe la Francaise raised its holdings in Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 501 shares in the last quarter. Arlington Trust Co LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $35,000. Finally, Kilter Group LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $35,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.7%

NYSE BMY opened at $62.46 on Friday. The stock has a market capitalization of $127.59 billion, a P/E ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.19. Bristol Myers Squibb Company has a 52-week low of $45.20 and a 52-week high of $68.64. The firm has a 50-day moving average price of $62.80 and a 200 day moving average price of $59.94. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 62.78% and a net margin of 18.47%. The company had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the previous year, the company earned $1.63 EPS. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. Equities research analysts expect that Bristol Myers Squibb Company will post 6.37 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Truist Financial set a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday. Guggenheim restated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Wells Fargo & Company reduced their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, October 13th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Finally, Morgan Stanley dropped their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.46.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.